- Home
- BNY vs CDTX Comparison
BNY vs CDTX Comparison
Compare BNY & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNY
- CDTX
- Stock Information
- Founded
- BNY 2001
- CDTX 2012
- Country
- BNY United States
- CDTX United States
- Employees
- BNY N/A
- CDTX N/A
- Industry
- BNY Trusts Except Educational Religious and Charitable
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BNY Finance
- CDTX Health Care
- Exchange
- BNY Nasdaq
- CDTX Nasdaq
- Market Cap
- BNY 249.4M
- CDTX 259.0M
- IPO Year
- BNY N/A
- CDTX 2015
- Fundamental
- Price
- BNY $10.22
- CDTX $18.37
- Analyst Decision
- BNY
- CDTX Strong Buy
- Analyst Count
- BNY 0
- CDTX 8
- Target Price
- BNY N/A
- CDTX $38.00
- AVG Volume (30 Days)
- BNY 52.7K
- CDTX 148.0K
- Earning Date
- BNY 01-01-0001
- CDTX 05-14-2025
- Dividend Yield
- BNY 3.93%
- CDTX N/A
- EPS Growth
- BNY N/A
- CDTX N/A
- EPS
- BNY N/A
- CDTX N/A
- Revenue
- BNY N/A
- CDTX $1,275,000.00
- Revenue This Year
- BNY N/A
- CDTX N/A
- Revenue Next Year
- BNY N/A
- CDTX N/A
- P/E Ratio
- BNY N/A
- CDTX N/A
- Revenue Growth
- BNY N/A
- CDTX N/A
- 52 Week Low
- BNY $8.60
- CDTX $10.00
- 52 Week High
- BNY $10.80
- CDTX $28.42
- Technical
- Relative Strength Index (RSI)
- BNY 47.44
- CDTX 35.44
- Support Level
- BNY $10.11
- CDTX $19.83
- Resistance Level
- BNY $10.39
- CDTX $23.76
- Average True Range (ATR)
- BNY 0.10
- CDTX 1.56
- MACD
- BNY 0.00
- CDTX -0.45
- Stochastic Oscillator
- BNY 63.24
- CDTX 4.94
About BNY BlackRock New York Municipal Income Trust
Blackrock NY Municipal Income Tr has an investment objective to provide current income exempt from regular U.S. federal income tax and New York State and New York City personal income taxes. The Trust seeks to achieve its investment objective by investing primarily in municipal bonds exempt from U.S. federal income taxes and New York State and New York City personal income taxes.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.